

III. 研究成果の刊行に関する一覧表レイアウト

書籍

著者氏名	論文タイトル名	書籍全体の編集者名	書 籍 名	出版社名	出版地	出版年	ページ
特記なし							

雑誌

発表者氏名	論文タイトル名	発表誌名	巻号	ページ	出版年
Mino M, Sano A, Kakazu E, Matsubara H, Kakisaka K, Kogure T, Sekine K, Aoki Y, Imamura M, Matsuda M, Yamazoe T, Mori T, Yoshio S, Inoue J, Masamune A, <u>Kanto T.</u>	Differences in branched-chain amino acid to tyrosine ratio (BTR) among etiologies of chronic liver disease progression compared to healthy adults.	<i>J Gastroenterol.</i>	doi: 10.1007/s00535-024-02092-0. Online ahead of print. PMID: 38530472		2024
Ohfuji S, Tanaka A, Kogiso T, <u>Kanto T*</u> .	Epidemiology of Fontan-associated liver disease in Japan: Results from a nationwide survey in 2021.	<i>Hepatol Res.</i>	doi: 10.1111/hepr.14040. Online ahead of print. PMID: 38526972		2024
Okushin K, Tateishi R, Hirakawa S, Tachimori H, Uchino K, Nakagomi R, Yamada T, Nakatsuka T, Minami T, Sato M, Fujishiro M, Hasegawa K, Eguchi Y, <u>Kanto T.</u> , Yoshiji H, Izumi N, Kudo M, Koike K.	The impact of COVID-19 on the diagnosis and treatment of HCC: analysis of a nationwide registry for advanced liver disease (REAL).	<i>Sci Rep</i>	Feb 3;14(1):2826. doi: 10.1038/s41598-024-53199-6.PMID: 38310156		2024

Kawai Y, Watanabe Y, Omae Y, Miyahara R, Khor SS, Noiri E, Kitajima K, Shimanuki H, Gatanaga H, Hata K, Hattori K, Iida A, Ishibashi-Ueda H, Kaname T, <u>Kanto T</u> , Matsumura R, Miyo K, Noguchi M, Ozaki K, Sugiyama M, Takahashi A, Tokuda H, Tomita T, Umezawa A, Watanabe H, Yoshida S, Goto YI, Maruoka Y, Matsubara Y, Niida S, Mizokami M, Tokunaga K.	Exploring the genetic diversity of the Japanese population: Insights from a large-scale whole genome sequencing analysis	<i>PLoS Genet.</i>	19(12):e1010625. doi: 10.1371/journal.pgen.1010625. eCollection 2023 Dec. PMID: 38060463		2023
Murai K, Hikita H, Kodama T, Kaibori M, Nishimura Y, Tatsumi T, Yamada T, <u>Kanto T</u> , Mochida S, Takehara T.	The impact of the COVID-19 pandemic on hepatocellular carcinoma diagnosis and treatment in Japan: A multicenter collaborative observational study.	<i>Hepatol Res.</i>	doi: 10.1111/hepr.13990.		2023
Takahama S, Yoshio S, Masuta Y, Murakami H, Sakamori R, Kaneko S, Honda T, Murakawa M, Sugiyama M, Kurosaki M, Asahina Y, Takehara T, Appay V, <u>Kanto T</u> , Yamamoto T	Hepatitis B surface antigen reduction is associated with hepatitis B core-specific CD8+ T cell quality.	<i>Front Immunol</i>			2023
Tsutsui Y, Mori T, Yoshio S, Sato M, Sakata T, Yoshida Y, Kawai H, Yoshikawa S, Yamazoe T, Matsuda M, Kakazu E, Osawa Y, Oyama C, Tamura-Nakano M, Kawaguchi T, Yoshizumi T, <u>Kanto T</u> .	Exercise changes the intrahepatic immune cell profile and inhibits the progression of nonalcoholic steatohepatitis in a mouse model.	<i>Hepatol Commun</i>	7(10):e0236. doi: 10.1097/HCC9.0000000000000236. eCollection 2023 Oct 1.		2023
Setoyama H, Nishida N, Nagashima S, Ko K, Yamazoe T, Tanaka Y, Mizokami M, Tanaka J, <u>Kanto T</u> .	Dried blood spot-based host genome analysis technique targeting pathological associations with hepatitis B: Development and clinical application in the Cambodian population.	<i>Hepatol Res</i>	doi: 10.1111/hepr.13949. Online ahead of print. PMID: 37522242		2023

Tomiyama T, Suzuki R, Harada N, Tamura T, Toshida K, Kosai-Fujimoto Y, Tomino T, Yoshiya S, Nagao Y, Takeishi K, Itoh S, Kobayashi N, Ito H, Yoshio S, <u>Kanto T</u> , Yoshizumi T, Fukuhara T.	A third dose of the BNT162b2 mRNA vaccine sufficiently improves the neutralizing activity against SARS-CoV-2 variants in liver transplant recipients.	<i>Front Cell Infect Microbiol</i>	doi: 10.3389/fcimb.2023.1197349. eCollection 2023.		2023
Mori T, Yoshio S, Yoshikawa S, Tsutsui Y, Sakata T, Yoshida Y, Sakamoto Y, Kawai H, Osawa Y, Yamazoe T, Aoki Y, Fletcher SP, <u>Kanto T</u> .*	Toll-like receptor 7 agonist, GS-986, is an immune-stimulant inducing follicular helper T cells and expanding HBs antigen-specific B cells in vitro.	<i>Liver Int</i> ,	43(6)	1213-1224	2023
<u>Nobuharu Tamaki</u> , Mayu Higuchi, Taisei Keitoku, Yuta Yamazaki, Naoki Uchihara, Keito Suzuki, Yuki Tanaka, Haruka Miyamoto, Michiko Yamada, Risa Okada, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Yutaka Yasui, Kaoru Tsuchiya, Hiroyuki Nakanishi, <u>Tatsuya Kanto</u> , Masayuki Kurosaki, Namiki Izumi	Magnetic resonance elastography for prediction of hepatocellular carcinoma in chronic hepatitis B	JGH Open			2024 in press
<u>Nobuharu Tamaki</u> , Shun-Ichi Wakabayashi, Takefumi Kimura, Yutaka Yasui, Kaoru Tsuchiya, Hiroyuki Nakanishi, Daniel Q Huang, Takeji Umemura, Masayuki Kurosaki, Namiki Izumi	Glycemic control target for liver and cardiovascular events risk in metabolic dysfunction-associated steatotic liver disease	Hepatol Res	doi: 10.1111/hepr.14025. Online ahead of print.		2024

Keito Suzuki, Nobuharu Tamaki , Masayuki Kurosaki, Yuka Takahashi, Yudai Yamazaki, Naoki Uchihara, Yuki Tanaka, Haruka Miyamoto, Michiko Yamada, Taisei Keitoku, Risa Okada, Mayu Higuchi, Kenta Takaura, Shohei Tanaka, Chiaki Maeyashiki, Yutaka Yasui, Kaoru Tsuchiya, Hiroyuki Nakanishi, Namiki Izumi.	Concordance between metabolic dysfunction- associated steatotic liver disease and nonalcoholic fatty liver disease	<i>Hepatol Res</i>	doi: 10.1111/hepr. 14011. Online ahead of print.		2024
Wakabayashi SI, Tamaki N , Kimura T, Umemura T, Kurosaki M, Izumi N.	Natural history of lean and non-lean metabolic dysfunction-associated steatotic liver disease	<i>J Gastroenterol</i>	doi: 10.1007/s005 35-024- 02093-z. Online ahead of print.		2024
Lee SW, Huang DQ, Bettencourt R, Ajmera V, Tincopa M, Nouredin N, Amangurbanova M, Siddiqi H, Madamba E, Majzoub AM, Nayfeh T, Tamaki N , Izumi N, Nakajima A, Yoneda M, Idilman R, Gumussoy M, Oz DK, Erden A, Loomba R.	Low liver fat in non- alcoholic steatohepatitis- related significant fibrosis and cirrhosis is associated with hepatocellular carcinoma, decompensation and mortality	<i>Aliment Pharmacol Ther</i>	59(1)	80-88	2024
Tan DJH, Ng CH, Muthiah M, Yong JN, Chee D, Teng M, Wong ZY, Zeng RW, Chin YH, Wang JW, Danpanichkul P, Rajaram RB, DasGupta R, Suzuki H, Takahashi H, Tamaki N , Dan YY, Lui R, Duseja A, Siddiqui MS, Yeoh KG, Sanyal A, Wijarnpreecha K, Loomba R, Mantzoros CS, Huang DQ.	Rising global burden of cancer attributable to high BMI from 2010 to 2019	<i>Metabolism</i>	doi: 10.1016/j.met abol.2023.15 5744. Epub 2023 Nov 27.		2023

<p>Tan DJH, Tang ASP, Lim WH, Ng CH, Nah B, Fu C, Xiao J, Koh B, Tay PWL, Tan EX, Teng M, Syn N, Muthiah MD, Tamaki N, Lee SW, Kim BK, Yau T, Vogel A, Loomba R, Huang DQ.</p>	<p>Survival Trends in Sorafenib for Advanced Hepatocellular Carcinoma: A Reconstructed Individual Patient Data Meta-Analysis of Randomized Trials</p>	<p><i>Liver Cancer</i></p>	<p>12(5):</p>	<p>445-456</p>	<p>2023</p>
<p>Kirino S, Tamaki N, Kurosaki M, Takahashi Y, Higuchi M, Itakura Y, Tanaka Y, Inada K, Ishido S, Yamashita K, Nobusawa T, Matsumoto H, Hayakawa Y, Kakegawa T, Takaura K, Tanaka S, Maeyashiki C, Kaneko S, Yasui Y, Tsuchiya K, Nakanishi H, Okamoto R, Izumi N.</p>	<p>Detecting advanced liver fibrosis using ultrasound shear wave velocity measurement in the general population</p>	<p><i>Quant Imaging Med Surg</i></p>	<p>13(10)</p>	<p>6493-6502.</p>	<p>2023</p>
<p>Uojima H, Nakabayashi K, Yamasaki K, Sugiyama M, Ishii N, Shirabe K, Kyoutou T, Ueda K, Takahama Y, Tamaki N, Kurosaki M, Hidaka H, Kusano C, Amano K, Kawaguchi T, Taketomi A, Joshita S, Umemura T, Murakawa M, Asahina Y, Suzuki T, Matsuura K, Nishimura T, Iijima H, Sakamoto K, Ito K, Nishina S, Hino K, Toyoda H, Yatsuhashi H, Kage M, Mizokami M.</p>	<p>New chemiluminescent enzyme immunoassay for quantitative measurement of Mac-2 binding protein glycosylation isomer in chronic liver disease</p>	<p><i>J Gastroenterol</i></p>	<p>;58(12)</p>	<p>1252-1260.</p>	<p>2023</p>

Yamada-Shimizu M, Tamaki N , Kurosaki M, Uchihara N, Suzuki K, Tanaka Y, Miyamoto H, Ishido S, Nobusawa T, Matsumoto H, Keitoku T, Higuchi M, Takaura K, Tanaka S, Maeyashiki C, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Izumi N.	A Comparison of Alanine Aminotransferase Normalization between Pemafibrate and Bezafibrate in Patients with Nonalcoholic Fatty Liver Disease	<i>Intern Med</i>	doi: 10.2169/internalmedicine.2248-23. Online ahead of print.		2023
Chan KE, Ong EYH, Chung CH, Ong CEY, Koh B, Tan DJH, Lim WH, Yong JN, Xiao J, Wong ZY, Syn N, Kaewdech A, Teng M, Wang JW, Chew N, Young DY, Know A, Siddiqui MS, Huang DQ, Tamaki N , Wong VW, Mantzoros CS, Sanyal A, Nouredin M, Ng CH, Muthiah M.	Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies	<i>Clin Gastroenterol Hepatol</i>	22(3)	488-498.	2023
Nouredin N, Ajmera V, Bergstrom J, Bettencourt R, Huang DQ, Siddiqi H, Majzoub AM, Nayfeh T, Tamaki N , Izumi N, Nakajima A, Idilman R, Gumussoy M, Oz DK, Erden A, Loomba R.	MEFIB-Index and MAST-Score in the assessment of hepatic decompensation in metabolic dysfunction-associated steatosis liver disease-Individual participant data meta-analyses	<i>Aliment Pharmacol Ther</i>	58(9)	856-865	2023
Ishido S, Tamaki N , Uchihara N, Suzuki K, Tanaka Y, Miyamoto H, Yamada M, Matsumoto H, Nobusawa T, Keitoku T, Takaura K, Tanaka S, Maeyashiki C, Yasui Y, Takahashi Y, Tsuchiya K, Nakanishi H, Itakura J, Kurosaki M, Izumi N.	Switching from entecavir to tenofovir alafenamide for maintaining complete virological response in chronic hepatitis B	<i>JGH Open</i>	7(8)	567-571	2023

En Li Cho E, Ang CZ, Quek J, Fu CE, Lim LKE, Heng ZEQ, Tan DJH, Lim WH, Yong JN, Zeng R, Chee D, Nah B, Lesmana CRA, Bwa AH, Win KM, Faulkner C, Aboona MB, Lim MC, Syn N, Kulkarni AV, Suzuki H, Takahashi H, Tamaki N , Wijampreecha K, Huang DQ, Muthiah M, Ng CH, Loomba R.	Global prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus: an updated systematic review and meta-analysis	Gut	72(11)	:2138-2148	2023
Huang DQ, Nouredin N, Ajmera V, Amangurbanova M, Bettencourt R, Truong E, Gidener T, Siddiqi H, Majzoub AM, Nayfeh T, Tamaki N , Izumi N, Yoneda M, Nakajima A, Idilman R, Gumussoy M, Oz DK, Erden A, Allen AM, Nouredin M, Loomba R.	Type 2 diabetes, hepatic decompensation, and hepatocellular carcinoma in patients with non-alcoholic fatty liver disease: an individual participant-level data meta-analysis	<i>Lancet Gastroenterol Hepato</i>	8(9)	829-836	2023
Ishido S, Tamaki N , Kurosaki M, Mori N, Tsuji K, Hasebe C, Mashiba T, Ochi H, Yasui Y, Akahane T, Furuta K, Kobashi H, Fujii H, Ishii T, Marusawa H, Kondo M, Kusakabe A, Yoshida H, Uchida Y, Tada T, Nakamura S, Mitsuda A, Ogawa C, Arai H, Murohisa T, Uebayashi M, Izumi N.	Necessity for surveillance for hepatocellular carcinoma in older patients with chronic hepatitis C who achieved sustained virological response	<i>JGH Open</i>	7(6)	:424-430	2023

Ishido S, Tamaki N , Takahashi Y, Uchihara N, Suzuki K, Tanaka Y, Miyamoto H, Yamada M, Matsumoto H, Nobusawa T, Keitoku T, Takaura K, Tanaka S, Maeyashiki C, Yasui Y, Tsuchiya K, Nakanishi H, Kurosaki M, Izumi N.	Risk of cardiovascular disease in lean patients with nonalcoholic fatty liver disease	<i>BMC Gastroenterol</i>	17;23(1):211		2023
Shimizu R, Murai K, Tanaka K, Sato Y, Takeda N, Nakasyo S, Shirasaki T, Kawaguchi K, Shimakami T , Nio K, Nakaya Y, Kagiwada H, Horimoto K, Mizokami M, Kaneko S, Murata K, Yamashita T, Honda M.	Nucleos(t)ide analogs for hepatitis B virus infection differentially regulate the growth factor signaling in hepatocytes.	<i>Hepatology Commun.</i>	8(1)	E0351	2024
Hayashi T, Hayashi K, Terashima T, Nishitani M, Orita N, Miyazawa M, Seki A, Nakagawa H, Nio K, Iida N, Yamada S, Takatori H, Shimakami T , Yamashita T.	Photodynamic therapy with talaporfin sodium for endoscopically unresectable gastric cancer using a novel simultaneous light-emitting method.	<i>DEN Open</i>	4(1)	E334	2024
出島彰宏, 島上哲朗 , 寺島健志, 堀井里和, 山田真也, 丹尾幸樹, 鷹取元, 荒井邦明, 山下竜也, 本多政夫, 金子周一, 山下太郎.	オンラインツールを用いた指定医療機関拡充によるC型慢性肝疾患患者への治療導入の促進	<i>肝臓</i>	65(3)	139-142	2024
Yamamoto M, Terashima T, Yamashita T, Seki A, Nakagawa H, Nio K, Shimakami T , Takatori H, Arai K, Mizukoshi E, Honda M, Takeuchi S, Yamashita T.	Successful second-line treatment with cabozantinib for hepatocellular carcinoma harboring cytoplasmic mesenchymal-epithelial transition factor amplification.	<i>Hepatology Res.</i>	54(3)	315-319	2024

磯田広史, 榎本大, 高橋宏和, 大野高嗣, 井上泰輔, 池上正, 井出達也, 徳本良雄, 小川浩司, 瀬戸山博子, 内田義人, 橋本まさみ, 廣田健一, 柿崎暁, 立木佐知子, 井上貴子, 遠藤美月, 島上哲朗, 荒生祥尚, 井上淳, 末次淳, 永田賢治, 是永匡紹.	肝疾患診療連携拠点病院における肝炎医療コーディネートナーの現状(第2報)	肝臓	64(10)	510-513	2024
磯田 広史, 大枝 敏, 古賀 俊六, 小谷 和彦, 島上 哲朗, 金子周一, 高橋 宏和.	オンライン超音波検査システムによる遠隔診療支援の試み 肝がん対策に向けて.	糖尿病インフォマティクス学会誌	21	11-14	2023
Shirasaki T, Murai K, Ishida A, Kuroki K, Kawaguchi K, Wang Y, Yamanaka S, Yasukawa R, Kawasaki N, Li YY, Shimakami T, Sumiyadorj A, Nio K, Sugimoto S, Orita N, Takayama H, Okada H, Thi Bich PD, Iwabuchi S, Hashimoto S, Ide M, Tabata N, Ito S, Matsushima K, Yanagawa H, Yamashita T, Kaneko S, Honda M.	Functional involvement of endothelial lipase in hepatitis B virus infection.	Hepatology Commun.	7(9)	E0206	2023
Orita N, Kawaguchi K, Honda M, Shimode T, Hayakawa N, Terashima T, Komura T, Nishikawa M, Horii R, Nio K, Shimakami T, Takatori H, Arai K, Sakai Y, Yamashita T, Mizukoshi E, Kaneko S, Kagaya T, Yamashita T.	Aldo-keto reductase family 1 member B10 is regulated by nucleos(t)ide analogues for chronic hepatitis B.	Biochem Biophys Res Commun.	674	133-139	2023
Doan PTB, Nio K, Shimakami T, Kuroki K, Li YY, Sugimoto S, Takayama H, Okada H, Kaneko S, Honda M, Yamashita T.	Super-Resolution Microscopy Analysis of Hepatitis B Viral cccDNA and Host Factors.	Viruses.	15(5)	1178	2023

Suda T, Takatori H, Hayashi T, Kaji K, Nio K, Terashima T, Shimakami T, Arai K, Yamashita T, Mizukoshi E, Honda M, Okumura K, Kozaka K, Yamashita T.	Plasma Antithrombin III Levels Can Be a Prognostic Factor in Liver Cirrhosis Patients with Portal Vein Thrombosis.	<i>Int J Mol Sci.</i>	24(9)	7732	2023
Hayashi T, Terashima T, Nishitani M, Orita N, Miyazawa M, Seki A, Nakagawa H, Nio K, Iida N, Yamada S, Takatori H, Shimakami T, Yamashita T.	Gastroduodenitis Associated with Active Ulcerative Colitis Treated with Infliximab~Different Clinical Course in the Colon and Gastroduodenal Lesions~.	<i>Intern Med.</i>	63(7)	929-935	2024
Miyazawa M, Yanagi M, Chiba T, Kido H, Matsuo T, Nishitani M, Orita N, Takata N, Hayashi T, Seki A, Nakagawa H, Nio K, Terashima T, Iida N, Yamada S, Takatori H, Shimakami T, Arai K, Yamashita T, Mizukoshi E, Honda M, Yamashita T.	Post- allogeneic Hematopoietic Stem Cell Transplantation Portal Hypertension Not Associated with Liver Cirrhosis, Veno-occlusive Disease, or Graft-versus-host Disease: A Case Report.	<i>Intern Med.</i>	In press		2023 online
Yoshimaru Y, Nagaoka K, Tanaka K, Narahara S, Inada H, Kurano S, Tokunaga T, Iio E, Watanabe T, Setoyama H, Tateyama M, Yoshida K, Tsunoda T, Nakamura Y, Tanaka M, Sasaki Y, Tanaka Y.	A randomized phase I / II study of vascular endothelial growth factor receptor peptide vaccines for patients with hepatocellular carcinoma.	<i>Hepatol Res.</i>	doi: 10.1111/hepr.13995.		2023
Nagaoka K, Bai X, Liu D, Cao K, Mulla J, Ji C, Chen H, Nisar MA, Bay A, Mueller W, Hildebrand G, Gao JS, Lu S, Setoyama H, Tanaka Y, Wands JR, Huang CK.	Elevated 2-oxoglutarate antagonizes DNA damage responses in cholangiocarcinoma chemotherapy through regulating aspartate beta-hydroxylase.	<i>Cancer Lett.</i>	doi: 10.1016/j.canlet.2023.216493.		2024
瀬戸山博子	各種医療制度活用において期待される肝炎医療コーディネーターの役割と課題	肝胆膵	88(2)	209-214	2024

瀬戸山 博子, 野村真希, 矢田 ともみ, 吉丸 洋子, 榎原 哲史, 稲田 浩気, 田中 健太郎, 蔵野 宗太郎, 徳永 堯之, 飯尾 悦子, 長岡 克弥, 渡邊 丈久, 江口 有一郎, 田中 靖人	肝炎医療コーディネーター活動継続における肝疾患診療連携拠点病院の役割	肝臓	64(11)	583-586	2023
廣田 健一, 井上 貴子, 小川 浩司, 荒生 祥尚, 遠藤 美月, 池上 正, 戸島 洋貴, 末次 淳, 柿崎 暁, 瀬戸山 博子, 榎本 大, 是永 匡紹	肝炎ウイルス陽性者対策が急がれる非肝臓専門科は？	肝臓	64(11)	587-589	2023
磯田 広史, 榎本 大, 高橋 宏和, 大野 高嗣, 井上 泰輔, 池上 正, 井出 達也, 徳本 良雄, 小川 浩司, 瀬戸山 博子, 内田 義人, 橋本 まさみ, 廣田 健一, 柿崎 暁, 立木 佐知子, 井上 貴子, 遠藤 美月, 島上 哲朗, 荒生 祥尚, 井上 淳, 末次 淳, 永田 賢治, 是永 匡紹	肝疾患診療連携拠点病院における肝炎医療コーディネーターの現状 (第2報)	肝臓	64(10)	510-513	2023
大保 宏允, 稲田 浩気, 瀬戸山 博子, 榎原 哲史, 田中 健太郎, 蔵野 宗太郎, 徳永 堯之, 飯尾 悦子, 吉丸 洋子, 長岡 克弥, 渡邊 丈久, 田中 基彦, 立山 雅邦, 田中 靖人	抗凝固療法が著効したCOVID-19合併急性肝不全の2例	肝臓	64(6)	270-279	2023
竹内泰江、是永匡紹、 <u>考藤達哉</u> 。	肝炎医療コーディネーターの養成と活躍のための肝疾患診療連携拠点病院への支援 ―肝炎情報センターの取組について―	肝胆膵	88(2)	233-239	2024
竹内泰江、 <u>考藤達哉</u> 。	2030年の肝炎撲滅に向けた日本の立ち位置は？ - C型肝炎に対する国の総合的な対策 -	肝胆膵	85(1)	7-13	2022
村田 尚寛, 小高 明日香, 藤森 晶子, 西井 正造, 武部 貴則	ストリートメディカルで広がる新たな医療の起点	総合健診	50(6)	533-543	2023